196 related articles for article (PubMed ID: 30824643)
1. Factors Influencing Raynaud Condition Score Diary Outcomes in Systemic Sclerosis.
Pauling JD; Reilly E; Smith T; Frech TM
J Rheumatol; 2019 Oct; 46(10):1326-1334. PubMed ID: 30824643
[TBL] [Abstract][Full Text] [Related]
2. Evolving Symptom Characteristics of Raynaud's Phenomenon in Systemic Sclerosis and Their Association With Physician and Patient-Reported Assessments of Disease Severity.
Pauling JD; Reilly E; Smith T; Frech TM
Arthritis Care Res (Hoboken); 2019 Aug; 71(8):1119-1126. PubMed ID: 30133174
[TBL] [Abstract][Full Text] [Related]
3. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
[TBL] [Abstract][Full Text] [Related]
4. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
5. Use of Laser Speckle Contrast Imaging to Assess Digital Microvascular Function in Primary Raynaud Phenomenon and Systemic Sclerosis: A Comparison Using the Raynaud Condition Score Diary.
Pauling JD; Shipley JA; Hart DJ; McGrogan A; McHugh NJ
J Rheumatol; 2015 Jul; 42(7):1163-8. PubMed ID: 26034146
[TBL] [Abstract][Full Text] [Related]
6. Construct validity and reliability of the Assessment of Systemic Sclerosis-Associated Raynaud's Phenomenon (ASRAP) questionnaire.
Pauling JD; Yu L; Frech TM; Herrick AL; Hummers LK; Shah AA; Denton CP; Saketkoo LA; Withey J; Khanna D; Domsic RT
Rheumatology (Oxford); 2024 May; 63(5):1281-1290. PubMed ID: 37481713
[TBL] [Abstract][Full Text] [Related]
7. Hyperspectral imaging in systemic sclerosis-associated Raynaud phenomenon.
Teaw S; Gupta A; Williams A; Wilson FP; Sumpio BJ; Sumpio BE; Hinchcliff M
Arthritis Res Ther; 2023 Jan; 25(1):10. PubMed ID: 36670487
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of cilostazol for the treatment of Raynaud's phenomenon in systemic sclerosis patients.
Negrini S; Spanò F; Penza E; Rollando D; Indiveri F; Filaci G; Puppo F
Clin Exp Med; 2016 Aug; 16(3):407-12. PubMed ID: 26088182
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with Bosentan and Sildenafil improves Raynaud's phenomenon and fosters the recovery of microvascular involvement in systemic sclerosis.
Bellando-Randone S; Lepri G; Bruni C; Blagojevic J; Radicati A; Cometi L; De Paulis A; Matucci-Cerinic M; Guiducci S
Clin Rheumatol; 2016 Jan; 35(1):127-32. PubMed ID: 26631100
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report.
Pauling JD; Frech TM; Hughes M; Gordon JK; Domsic RT; Anderson ME; Ingegnoli F; McHugh NJ; Johnson SR; Hudson M; Boin F; Ong VH; Matucci-Cerinic M; Altorok N; Scolnik M; Nikpour M; Shah A; Pope JE; Khanna D; Herrick AL
J Scleroderma Relat Disord; 2018 Oct; 3(3):249-252. PubMed ID: 30705970
[TBL] [Abstract][Full Text] [Related]
11. Effect of Coping Strategies on Patient and Physician Perceptions of Disease Severity and Disability in Systemic Sclerosis.
DiRenzo DD; Smith TR; Frech TM; Shah AA; Pauling JD
J Rheumatol; 2021 Oct; 48(10):1569-1573. PubMed ID: 33934078
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.
Denton CP; Hachulla É; Riemekasten G; Schwarting A; Frenoux JM; Frey A; Le Brun FO; Herrick AL;
Arthritis Rheumatol; 2017 Dec; 69(12):2370-2379. PubMed ID: 29193819
[TBL] [Abstract][Full Text] [Related]
13. Factors Influencing Patient Decision-Making Concerning Treatment Escalation in Raynaud's Phenomenon Secondary to Systemic Sclerosis.
Hughes M; Huang S; Pauling JD; Sabbagh M; Khanna D
Arthritis Care Res (Hoboken); 2021 Dec; 73(12):1845-1852. PubMed ID: 34057304
[TBL] [Abstract][Full Text] [Related]
14. The burden of air pollution and temperature on Raynaud's phenomenon secondary to systemic sclerosis.
Schioppo T; De Lucia O; Murgo A; Caporali R; Orenti A; Boracchi P; Iodice S; Ubiali T; Bollati V; Ingegnoli F
Epidemiol Prev; 2020; 44(4):218-227. PubMed ID: 32921028
[TBL] [Abstract][Full Text] [Related]
15. Qualitative Interviews to Assess the Content Validity and Usability of the Electronic Raynaud Diary in Patients with Systemic Sclerosis.
Domsic RT; Pokrzywinski R; Stassek L; Benton WW; Vampola CL; Furst DE; Chung L; Steen V; Mayes MD; Shah AA; Molitor JA; Oliver K; Nagaraja V; Khanna D
ACR Open Rheumatol; 2023 Mar; 5(3):132-141. PubMed ID: 36727567
[TBL] [Abstract][Full Text] [Related]
16. Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), physician- and patient-rated global assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0, Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) (Mahler's Index), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), and Raynaud's Condition Score (RCS).
Pope J
Arthritis Care Res (Hoboken); 2011 Nov; 63 Suppl 11():S98-111. PubMed ID: 22588774
[No Abstract] [Full Text] [Related]
17. Therapeutic hypothermia after cardiac arrest in a patient with systemic sclerosis and Raynaud phenomenon.
Bakal K; Danckers M; Denson JL; Sauthoff H
Chest; 2015 Feb; 147(2):e27-e30. PubMed ID: 25644911
[TBL] [Abstract][Full Text] [Related]
18. Raynaud's phenomenon and its impact on activities in daily life during one year of follow-up in early systemic sclerosis.
Sandqvist G; Wollmer P; Scheja A; Wildt M; Hesselstrand R
Scand J Rheumatol; 2018 May; 47(3):206-209. PubMed ID: 28803485
[TBL] [Abstract][Full Text] [Related]
19. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
[TBL] [Abstract][Full Text] [Related]
20. The effect of silver fibre gloves on Raynaud's phenomenon in patients with systemic sclerosis: a double-blind randomized crossover trial.
Liem SIE; Hoekstra EM; Bonte-Mineur F; Magro Checa C; Schouffoer A; Allaart CF; Huizinga TWJ; Bergstra SA; de Vries-Bouwstra JK
Rheumatology (Oxford); 2023 Feb; 62(SI):SI74-SI81. PubMed ID: 35441683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
